Venable·IP / PATENT
Insulin Glargine Patent Spotlight: Lantus, Basaglar, Semglee, Rezvoglar
Venable's November 2026 Spotlight catalogs the patent claims challenged in pending litigation and IPRs over insulin glargine products, including Lantus, SoloSTAR, Basaglar, Semglee and Rezvoglar.
insulin-glarginelantusbasaglarsemgleerezvoglaranda-litigationiprpharma-patent-litigation
Read the original firm alert → Tuesday, November 10, 2026